CELLEBRATE: An Adaptive, Two-Stage, Double-Blind, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR With Placebo in Female Subjects With Persistent or Recurrent Stress Urinary Incontinence Following Surgical Treatment
Latest Information Update: 08 May 2025
At a glance
- Drugs Iltamiocel (Primary)
- Indications Urinary-Stress-Incontinence
- Focus Registrational; Therapeutic Use
- Acronyms CELLEBRATE
- Sponsors Cook MyoSite
Most Recent Events
- 29 Apr 2025 Planned End Date changed from 1 Feb 2026 to 1 Sep 2027.
- 29 Apr 2025 Planned primary completion date changed from 1 Feb 2025 to 1 Sep 2026.
- 11 Feb 2025 Planned primary completion date changed from 1 Jan 2025 to 1 Feb 2025.